Description General description A cell-permeable, reversible, substrate competitive, and specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor kinases with significantly lower IC50 values for IGF-1 than for insulin receptors. Induces apoptosis by downregulating the expression of phospho-Akt1 and Bcl-2; and increasing the expression of Bax, p53 and p21. Reported to enhance the radiosensitivity of human breast cancer cells. A cell-permeable, reversible, substrate competitive, and specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor tyrosine kinase activity. Exhibits lower IC50 values for IGF-1 than for the insulin receptor. Also inhibits insulin-stimulated cellular proliferation. Packaging 1 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target IGF-1 Product does not compete with ATP. Reversible: yes Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 2 months at -20°C. Other Notes Wen, B., et al. 2001. Br. J. Cancer85, 2017. Parrizas, M., et al. 1997. Endocrinology138, 1427. Ohmichi, M., et al. 1993. Biochemistry32, 4650.